vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and HARROW, INC. (HROW). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $89.1M, roughly 1.1× HARROW, INC.). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 7.4%, a 20.9% gap on every dollar of revenue. On growth, HARROW, INC. posted the faster year-over-year revenue change (33.3% vs 17.7%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $8.1M). Over the past eight quarters, HARROW, INC.'s revenue compounded faster (60.5% CAGR vs 30.6%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
DVAX vs HROW — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $89.1M |
| Net Profit | $26.9M | $6.6M |
| Gross Margin | — | 79.3% |
| Operating Margin | 22.4% | 17.5% |
| Net Margin | 28.4% | 7.4% |
| Revenue YoY | 17.7% | 33.3% |
| Net Profit YoY | 53.0% | -2.2% |
| EPS (diluted) | $0.21 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $89.1M | ||
| Q3 25 | $94.9M | $71.6M | ||
| Q2 25 | $95.4M | $63.7M | ||
| Q1 25 | $68.2M | $47.8M | ||
| Q4 24 | $72.0M | $66.8M | ||
| Q3 24 | $80.6M | $49.3M | ||
| Q2 24 | $73.8M | $48.9M | ||
| Q1 24 | $50.8M | $34.6M |
| Q4 25 | — | $6.6M | ||
| Q3 25 | $26.9M | $1.0M | ||
| Q2 25 | $18.7M | $5.0M | ||
| Q1 25 | $-96.1M | $-17.8M | ||
| Q4 24 | $7.0M | $6.8M | ||
| Q3 24 | $17.6M | $-4.2M | ||
| Q2 24 | $11.4M | $-6.5M | ||
| Q1 24 | $-8.7M | $-13.6M |
| Q4 25 | — | 79.3% | ||
| Q3 25 | — | 75.3% | ||
| Q2 25 | — | 74.5% | ||
| Q1 25 | — | 67.5% | ||
| Q4 24 | — | 78.8% | ||
| Q3 24 | — | 75.6% | ||
| Q2 24 | — | 74.4% | ||
| Q1 24 | — | 69.5% |
| Q4 25 | — | 17.5% | ||
| Q3 25 | 22.4% | 20.6% | ||
| Q2 25 | 15.1% | 17.9% | ||
| Q1 25 | -34.7% | -23.5% | ||
| Q4 24 | -2.3% | 19.3% | ||
| Q3 24 | 12.5% | 2.7% | ||
| Q2 24 | 7.0% | 3.1% | ||
| Q1 24 | -35.0% | -20.0% |
| Q4 25 | — | 7.4% | ||
| Q3 25 | 28.4% | 1.4% | ||
| Q2 25 | 19.6% | 7.8% | ||
| Q1 25 | -141.0% | -37.2% | ||
| Q4 24 | 9.8% | 10.1% | ||
| Q3 24 | 21.8% | -8.6% | ||
| Q2 24 | 15.4% | -13.2% | ||
| Q1 24 | -17.2% | -39.2% |
| Q4 25 | — | $0.20 | ||
| Q3 25 | $0.21 | $0.03 | ||
| Q2 25 | $0.14 | $0.13 | ||
| Q1 25 | $-0.77 | $-0.50 | ||
| Q4 24 | $0.07 | $0.19 | ||
| Q3 24 | $0.12 | $-0.12 | ||
| Q2 24 | $0.08 | $-0.18 | ||
| Q1 24 | $-0.07 | $-0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $72.9M |
| Total DebtLower is stronger | — | $250.0M |
| Stockholders' EquityBook value | $534.1M | $52.4M |
| Total Assets | $946.5M | $399.5M |
| Debt / EquityLower = less leverage | — | 4.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $72.9M | ||
| Q3 25 | $160.2M | $74.3M | ||
| Q2 25 | $99.1M | $53.0M | ||
| Q1 25 | $51.7M | $66.7M | ||
| Q4 24 | $95.9M | $47.2M | ||
| Q3 24 | $119.3M | $72.6M | ||
| Q2 24 | $112.5M | $71.0M | ||
| Q1 24 | $132.0M | $76.0M |
| Q4 25 | — | $250.0M | ||
| Q3 25 | — | $347.2M | ||
| Q2 25 | — | $250.6M | ||
| Q1 25 | — | $256.9M | ||
| Q4 24 | — | $262.7M | ||
| Q3 24 | — | $230.7M | ||
| Q2 24 | — | $236.3M | ||
| Q1 24 | — | $243.4M |
| Q4 25 | — | $52.4M | ||
| Q3 25 | $534.1M | $47.0M | ||
| Q2 25 | $494.2M | $49.7M | ||
| Q1 25 | $530.9M | $56.5M | ||
| Q4 24 | $596.8M | $69.7M | ||
| Q3 24 | $681.4M | $58.0M | ||
| Q2 24 | $642.8M | $58.5M | ||
| Q1 24 | $618.5M | $60.6M |
| Q4 25 | — | $399.5M | ||
| Q3 25 | $946.5M | $363.1M | ||
| Q2 25 | $918.4M | $345.0M | ||
| Q1 25 | $945.9M | $364.2M | ||
| Q4 24 | $986.3M | $389.0M | ||
| Q3 24 | $1.1B | $351.5M | ||
| Q2 24 | $1.0B | $306.6M | ||
| Q1 24 | $986.6M | $295.5M |
| Q4 25 | — | 4.77× | ||
| Q3 25 | — | 7.39× | ||
| Q2 25 | — | 5.05× | ||
| Q1 25 | — | 4.55× | ||
| Q4 24 | — | 3.77× | ||
| Q3 24 | — | 3.98× | ||
| Q2 24 | — | 4.04× | ||
| Q1 24 | — | 4.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $8.4M |
| Free Cash FlowOCF − Capex | $32.6M | $8.1M |
| FCF MarginFCF / Revenue | 34.4% | 9.1% |
| Capex IntensityCapex / Revenue | 1.3% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.26× | 1.27× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $43.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.4M | ||
| Q3 25 | $33.8M | $16.6M | ||
| Q2 25 | $23.4M | $-803.0K | ||
| Q1 25 | $-19.6M | $19.7M | ||
| Q4 24 | $53.0M | $-17.8M | ||
| Q3 24 | $19.5M | $3.0M | ||
| Q2 24 | $10.7M | $-2.7M | ||
| Q1 24 | $-16.7M | $-4.6M |
| Q4 25 | — | $8.1M | ||
| Q3 25 | $32.6M | $16.4M | ||
| Q2 25 | $22.0M | $-969.0K | ||
| Q1 25 | $-23.6M | $19.5M | ||
| Q4 24 | $49.5M | $-18.3M | ||
| Q3 24 | $18.1M | $2.3M | ||
| Q2 24 | $9.9M | $-3.1M | ||
| Q1 24 | $-17.4M | $-4.7M |
| Q4 25 | — | 9.1% | ||
| Q3 25 | 34.4% | 22.9% | ||
| Q2 25 | 23.0% | -1.5% | ||
| Q1 25 | -34.6% | 40.8% | ||
| Q4 24 | 68.8% | -27.4% | ||
| Q3 24 | 22.5% | 4.8% | ||
| Q2 24 | 13.5% | -6.3% | ||
| Q1 24 | -34.3% | -13.6% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | 1.3% | 0.3% | ||
| Q2 25 | 1.5% | 0.3% | ||
| Q1 25 | 5.8% | 0.4% | ||
| Q4 24 | 4.8% | 0.8% | ||
| Q3 24 | 1.7% | 1.2% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 1.5% | 0.3% |
| Q4 25 | — | 1.27× | ||
| Q3 25 | 1.26× | 16.26× | ||
| Q2 25 | 1.25× | -0.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | -2.62× | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
HROW
Segment breakdown not available.
